These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11328422)

  • 1. Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer.
    Furuya Y; Akakura K; Tanaka M; Ichikawa T; Igarashi T; Murakami S; Ito H
    Int J Urol; 2001 May; 8(5):222-6. PubMed ID: 11328422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiation monotherapy for prostate cancer.
    Akakura K; Furuya Y; Suzuki H; Komiya A; Ichikawa T; Igarashi T; Tanaka M; Murakami S; Ito H
    Int J Urol; 1999 Aug; 6(8):408-13. PubMed ID: 10466453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
    Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
    Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
    Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
    Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body re-irradiation therapy for locally recurrent prostate cancer after external-beam radiation therapy: Initial report.
    Janoray G; Reynaud-Bougnoux A; Ruffier-Loubière A; Bernadou G; Pointreau Y; Calais G
    Cancer Radiother; 2016 Jun; 20(4):275-81. PubMed ID: 27342944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy.
    Lai PP; Perez CA; Lockett MA
    Int J Radiat Oncol Biol Phys; 1992; 24(3):423-30. PubMed ID: 1399726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States.
    Sylvester J; Grimm P; Blasco J; Meier R; Spiegel J; Heaney C; Cavanagh W
    Urology; 2001 Aug; 58(2 Suppl 1):65-70. PubMed ID: 11502452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.
    Whittington R; Malkowicz SB; Machtay M; Van Arsdalen K; Barnes MM; Broderick GA; Wein AJ
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):673-80. PubMed ID: 9336149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.